期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

尿激酶型纤溶酶原激活物对乳腺癌转移的影响 被引量：2

原文传递
导出
摘要 乳腺癌在早期即可发生转移，严重影响生存质量。肿瘤侵袭转移是一个多步骤的复杂过程，包括肿瘤细胞的黏附和脱黏附，细胞外基质的降解和重建等过程。胞外基质降解是肿瘤浸润转移的首要步骤和分子基础，大量的研究资料表明，尿激酶型纤溶酶原激活物（uPA）参与细胞外基质降解，在肿瘤浸润和转移中起到主要作用。本研究旨在观察uPA在乳腺癌中的表达以及对乳腺癌侵袭能力的影响。
作者 董波 舒晓燕
机构地区 武汉市中心医院外科 黄石妇幼保健院
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2012年第8期1619-1619,共1页 Chinese Journal of Experimental Surgery
关键词 尿激酶型纤溶酶原激活物 乳腺癌转移 细胞外基质降解 肿瘤侵袭转移 肿瘤浸润转移 浸润和转移 生存质量 肿瘤细胞
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献4

  • 1Hoffmann G, Pollow K, Weikel W, et al. U- rokinase and plasminogen activator inhibi- tor status in primary ovarian carcinomas and ovarian metastatus compared to benign ovarian tumor as a function of histopatho- logical parameters. Clin Chem Lab Med, 1999,37:47-54.
  • 2Van der Brag ME, Henten-logmans SC, Berns EM, et al. Expres-sion of urokinase type plasminogen activator (uPA) and its inhibitorPAI-I in benign, borderline, ma- lignant primary and metastatic o-varian tumors Int. Cancer, 1996,69:475-479.
  • 3吴桂珠,郑秀.肿瘤的浸润、转移与uPA系统的关系[J].海峡预防医学杂志,2005,11(2):25-27. 被引量：4
  • 4李梦秋,陆茵.尿激酶型纤溶酶原激活物作用系统与肿瘤转移[J].实用肿瘤学杂志,2005,19(5):387-390. 被引量：3

二级参考文献42

  • 1Pyke C, Kristensen P, Ralfkiaer E, et al. The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma [J].Cancer Res, 1991,51(15): 4067-4071.
  • 2Riethdorf L, Kiethdorf S, Petersen S, et al. Urokinase gene expression indicates early invasive growth in squamous cell lesions of the uterine cervix [J]. Pathol, 1999, 189(2):245-250.
  • 3Fujishiro S, Kobayashi H, Terao T, et al. Urokinase type plasmlnogen activator as a predicator for lymph nodes metastasis of uterine cervical cancer [J]. Nippon Sanka Fujinka Gakkai Tasshi,1994, 46(2) :129-136.
  • 4Van der Burg ME, Henten-logmans SC, Berns EM, et al. Expression of urokinase type plasminogen activator(uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors Int [J]. Cancer, 1996, 69(6): 475-479.
  • 5Hoffmann G, Pollow K, Weikel W, et al. Urokinase and plasminogen activator inhibitor status in primary ovarian carcinomas and ovarian metastatus compared to benign ovarian tumor as a function of histopathological parameters [J]. Clin Chem Lab Med,1999, 37(1):47-54.
  • 6Nordengren J, Casslen B, Gustavsson B, et al. Discordant expression of mRNA and protein for urokinase and tissue plasminogen activators(u-PA, t-PA) in endometrical carcinoma [J]. Int Cancer,1998, 79(2):195-201.
  • 7Foca C, Moses EK, Quinn MA, et al. Differential mRNA expression of urokinase- type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas [J]. Gynecol Oncol, 2000, 79(2):244-250.
  • 8Feng Q, Liu Y, Liu K, et al. Expression of urokinase, plasminogen activator inhibitors and urokinase receptor in pregnant rhesus monkey uterus during early placentation [J]. Placenta, 2002, 21(2-3): 184-193.
  • 9Puricelli L, Proierrii CJ, Labriola L, et al. Heregulin inhibits proliferation Via ERKs and phosphatidyl-inositol-3 kinase action but regulates urokinase plasminogen activator independently of these pathways in metastatic mammary tumor cells [J]. Int J Cancer,2002,100(6): 642-53.
  • 10Jo M, Thomas KS, Wu L, et al. Solube urokinase type plasminogen activator receptor inhibits cancer cell growth and invasion by direct urokinase dependent effects on cell signaling [J]. J Biol Chem, 2003,278 (47): 46692-8.

共引文献5

同被引文献22

  • 1Carriero MV,Stoppelli MP.The urokinase-type plasminogen acti-vator and the generation of inhibitors of urokinase activity and sig-naling[J].Curr Pharm Des,2011(19):1944-1961.
  • 2Sorio C,Mafficini A,Furlan F,et al.Elevated urinary levels of uro-kinase-type plasminogen activator receptor(u PAR)in pancreatic ductal adenocarcinoma identify a clinically highrisk group[J].BMC Cancer,2011(11):448.
  • 3Kotzsch M,Magdolen V,Greither T,et al.Combined mRNA expres-sion levels of members of the urokinase plasminogen activator(u PA)system correlate with diseaseassociated survival of soft-tissue sarcoma patients[J].BMC Cancer,2011(11):273.
  • 4Halamkova J,Kiss I,Pavlovsky Z,et al.Clinical significance of the plasminogen activator system in relation to grade of tumor and treatment response in colorectal carcinoma patients[J].Neoplas-ma,2011(5):377-385.
  • 5Nowicki TS,Kummer NT,Iacob C,et al.Inhibition of u PAR and u PA reduces invasion in papillary thyroid carcinoma cells[J].La-ryngoscope,2010(7):1383-1390.
  • 6Zhang W,Ling D,Tan J,et al.Expression of urokinase plasmino-gen activator and plasminogen activator inhibitor type-1 in ovari-an cancer and its clinical significance[J].Oncol Rep,2013(2):637-645.
  • 7Jiang JT,Zhang LF,Zhou B,et al.Relationships of u PA and VEGF expression in esophageal cancer and microvascular density with tumorous invasion and metastasis[J].Asian Pac J Cancer Prev,2012(7):3379-3383.
  • 8Kwaan HC,Mc Mahon B.The role of plasminogen-plasmin system in cancer[J].Cancer Treat Res,2009(148):43-66.
  • 9Mc Mahon B,Kwaan HC.The plasminogen activator system and cancer[J].Pathophysiol Haemost Thromb,2008(3-4):184-194.
  • 10喻晓兵,戴虹,龙力,黄林英,杨絮.玻璃体腔注射抗血管内皮生长因子单克隆抗体Ranibizumab治疗视网膜静脉阻塞继发黄斑水肿[J].中华眼底病杂志,2008,24(3):219-220. 被引量：8

引证文献2

二级引证文献3

中华实验外科杂志
2012年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部